Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?

Please visit answersincme.com/EUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology and oncology discuss the role of cereblon E3 ligase modulators in patients with relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating cereblon (CRBN) E3 ligase modulators (CELMoDs) as therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM); Describe the clinical profiles of emerging CELMoDs for patients with RRMM; and Outline evidence-based strategies to optimize sequencing to CELMoDs for patients with RRMM, as they become available.

There are no comments yet.

Please log in to write the first comment.